Interleukin-1α protects against the toxicity associated with combined radiation and drug therapy

Evans, Mark J.; Kovacs, C. J.; Gooya, John; Harrell, J.P.

doi:10.1016/0360-3016(91)90109-h

Cited by 8 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some cytokines such as granulocyte colony stimulating factor (G-CSF), Interleukin-1 (IL-1) and Interleukin-11 (IL-11), etc. have been reported protecting hematopoiesis and immune system from radiation injury (26)(27)(28). To date five agents which are cytokines or recombinant growth factors have been approved by U.S. Food and Drug Administration (FDA) for hematopoietic ARS (H-ARS), including Neupogen (Filgramostim), Neulasta (PEGylated filgramostim), Leukine (Sargramostim), Nplate (Romiplostim) and Udenyca (Neulasta biosimilar) (29,30).…”

Section: Discussionmentioning

confidence: 99%

Regulation of Circulating miR-342-3p Alleviates the Radiation-Induced Immune System Injury

Wei,

Bai,

Zhang

et al. 2023

Radiation Research

View full text Add to dashboard Cite

Ionizing radiation in space, radiation devices or nuclear disasters are major threats to human health and public security. Expanding countermeasures for dealing with accidental or occupational radiation exposure is crucial for the protection of radiation injuries. Circulating microRNAs (miRNAs) have emerged as promising radiation biomarkers in recent years. However, the origin, distribution and functions of radiosensitive circulating miRNAs remain unclear, which obstructs their clinical applications in the future. In this study, we found that mmu-miR-342-3p (miR-342) in mouse serum presents a stable and significant decrease after X-ray total-body irradiation (TBI). Focusing on this miRNA, we investigated the influences of circulating miR-342 on the radiation-induced injury. Through tail vein injection of Cy5-labeled synthetic miR-342, we found the exogenous miR-342-Cy5 was mainly enriched in metabolic and immune organs. Besides, the bioinformatic analysis predicted that miR-342 might involve in immune-related processes or pathways. Further, mice were tail vein injected with synthetic miR-342 mimetics (Ago-miR-342) after irradiation to upregulate the level of miR-342 in circulating blood. The results showed that the upregulation of circulating miR-342 alleviated the radiation-induced depletion of CD3+CD4+ T lymphocytes and influenced the levels of IL-2 and IL-6 in irradiated mice. Moreover, the injection of Ago-miR-342 improved the survival rates of mice with acute radiation injury. Our findings demonstrate that upregulation of circulating miR-342 alleviates the radiation-induced immune system injury, which provides us new insights into the functions of circulating miRNAs and the prospect as the targets for mitigation of radiation injuries.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulation of Circulating miR-342-3p Alleviates the Radiation-Induced Immune System Injury

Wei,

Bai,

Zhang

et al. 2023

Radiation Research

View full text Add to dashboard Cite

show abstract

“…This assessment has stemmed from better survival rates with their use (13) or improved cell recovery and colony-forming ability (13,34). The improved survival after IL-1 with chemotherapy or irradiation is thought to be largely the result of its ability to induce hematologic recovery (7, 12), a hypothesis supported by observations that IL-1 is most effective in protecting against myelotoxic drugs rather than against those that are primarily nephrotoxic or cardiotoxic (18).…”

Section: Discussionmentioning

confidence: 99%

Hemopoietic Function After Use of IL-1 with Chemotherapy or Irradiation

Gardner¹,

McKinnon²,

Poretta

et al. 2003

The Journal of Immunology

View full text Add to dashboard Cite

IL-1 has putative chemo- and radioprotective properties, but its effects on primitive hemopoietic stem cell (PHSC) and early multilineage precursor function when given with these modalities is unknown. C57BL6/J (B6) mice, given IL-1 20 h before cyclophosphamide (200 mg/kg for four biweekly doses) or before irradiation (500 cGy), were sacrificed after 4 wk. Their marrow was used as donor cells, and that from B6-HbbdGpi1a (B6-GPI) mice was used as competitor cells in competitive repopulation. Percentages of B6 cells were measured at 30 and 150 days. Stem cell numbers were estimated using binomial statistics. IL-1 alone did not affect stem cell function. As expected, significant declines in early multilineage precursor and PHSC function occurred with chemotherapy and radiation alone. IL-1 with chemotherapy led to exacerbation of these losses in function and numbers (p < 0.05). A similar reduction in function occurred using IL-1 before irradiation. In summary, IL-1 with chemotherapy or radiation worsened chemotherapy- and radiation-induced functional damage to PHSC and other hemopoietic precursors, suggesting that improvements in survival do not necessarily translate into preservation of hemopoietic function.

show abstract

“…These factors can include chemotherapy, other biologic response modifiers such as radiosensitizers, cytokines, and growth factor inhibitors (e.g., anti-EGFr antibody). [69][70][71][72] For instance, DeNardo et al 109 demonstrated that the addition of paclitaxel can improve efficacy of radioimmunotherapy in an animal model without substantially increasing the toxicity. In their study using breast cancer xenografts, 79% of tumor-bearing animals responded to 90 Y-ChL6 alone but none were cured whereas 100% of animals responded when paclitaxel was given 6 or 24 hours after the same dose of 90 Y-ChL6 and 48% were cured.…”

Section: ) Calculated Dose Is Not Equal To Biologicmentioning

confidence: 99%

“…96 More details of radionuclide clinical studies are presented in recent reviews. 67,68,69,70 Some of the best response rates have been achieved in NHL, which is considered a relatively radiosensitive malignancy, and may be effectively treated with low dose rate radiation as provided by radionuclide therapy. 67 Table 7 lists several selected studies from a few of the promising radioimmunoconjugates currently under investigation.…”

Section: D) Was Background Subtraction Performed?mentioning

confidence: 99%

Clinical Trial Design and Scoring of Radionuclide Therapy Endpoints: Normal Organ Toxicity and Tumor Response

Meredith

2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in a progressive series of clinical trials after basic science, human cell culture and animal model studies. Toxicities during these trials are graded using common scoring systems that are in widespread use such as the Common Toxicity Criteria from the National Cancer Institute. Information on normal tissue toxicity from radionuclides is more limited than that from external beam radiation and is more variable. Variability is likely due to many biologic factors as well as less precise dose quantitation than those used in external beam radiation practice. As expected based on known radiobiologic effects, tolerance to radionuclide therapy appears to exceed that from high dose rate external beam radiation in most organs. Although the correlation between reported dose estimates and toxicity has progressively and substantially improved over the past two decades, further progress is needed to establish optimal toxicity predictive relationships. Continued refinement of dosimetry techniques and standardization is expected to increase the accuracy and comparability of radiation dose reports between institutions as well as improve dose/response correlation.

show abstract

Interleukin-1α protects against the toxicity associated with combined radiation and drug therapy

Cited by 8 publications

References 2 publications

Regulation of Circulating miR-342-3p Alleviates the Radiation-Induced Immune System Injury

Regulation of Circulating miR-342-3p Alleviates the Radiation-Induced Immune System Injury

Hemopoietic Function After Use of IL-1 with Chemotherapy or Irradiation

Clinical Trial Design and Scoring of Radionuclide Therapy Endpoints: Normal Organ Toxicity and Tumor Response

Contact Info

Product

Resources

About